Although senescence has the greatest impact on ICB therapies, mechanistic studies and drug development targeting APOE (to reduce or inhibit APOE expression and thereby reduce immune cell senescence and immunotherapy resistance) and sirt1-7 (to study the common pathway that activates the sirt family of cancer inhibitory pathways and senescence-delaying pathways) may be the key to combining senescence therapies with immunotherapies in the treatment of tumors. The gene discussed is APOE; the disease is cancer.